{"id":"https://openalex.org/W2965728877","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.3068","title":"AFM11, a CD19/CD3 bispecific tandab, to facilitate T-cell-mediated killing of CD19+ cells.","display_name":"AFM11, a CD19/CD3 bispecific tandab, to facilitate T-cell-mediated killing of CD19+ cells.","publication_year":2013,"publication_date":"2013-05-20","ids":{"openalex":"https://openalex.org/W2965728877","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.3068","mag":"2965728877"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.15_suppl.3068","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.3068","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.3068","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067216355","display_name":"Eugene A. Zhukovsky","orcid":"https://orcid.org/0000-0003-1822-8946","observed_orcids":["https://orcid.org/0000-0003-1822-8946"]},"institutions":[{"id":"https://openalex.org/I4210116339","display_name":"Affimed Therapeutics (Germany)","ror":"https://ror.org/02fdw0g32","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210116339"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Eugene Zhukovsky","raw_affiliation_strings":["Affimed Therapeutics AG, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affimed Therapeutics AG, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210116339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086339650","display_name":"Uwe Reusch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116339","display_name":"Affimed Therapeutics (Germany)","ror":"https://ror.org/02fdw0g32","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210116339"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Uwe Reusch","raw_affiliation_strings":["Affimed Therapeutics AG, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affimed Therapeutics AG, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210116339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005127027","display_name":"Carmen Burkhardt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116339","display_name":"Affimed Therapeutics (Germany)","ror":"https://ror.org/02fdw0g32","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210116339"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Carmen Burkhardt","raw_affiliation_strings":["Affimed Therapeutics AG, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affimed Therapeutics AG, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210116339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030089903","display_name":"Stefan H.J. Knackmuss","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116339","display_name":"Affimed Therapeutics (Germany)","ror":"https://ror.org/02fdw0g32","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210116339"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Stefan Knackmuss","raw_affiliation_strings":["Affimed Therapeutics, Inc, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affimed Therapeutics, Inc, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210116339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065925693","display_name":"Ivica Fucek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116339","display_name":"Affimed Therapeutics (Germany)","ror":"https://ror.org/02fdw0g32","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210116339"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Ivica Fucek","raw_affiliation_strings":["Affimed Therapeutics AG, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affimed Therapeutics AG, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210116339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056431731","display_name":"Markus Eser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116339","display_name":"Affimed Therapeutics (Germany)","ror":"https://ror.org/02fdw0g32","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210116339"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Markus Eser","raw_affiliation_strings":["Affimed Therapeutics AG, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affimed Therapeutics AG, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210116339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065739283","display_name":"Fionnuala McAleese","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116339","display_name":"Affimed Therapeutics (Germany)","ror":"https://ror.org/02fdw0g32","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210116339"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Fionnuala McAleese","raw_affiliation_strings":["Affimed Therapeutics AG, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affimed Therapeutics AG, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210116339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075328300","display_name":"Kristina Ellwanger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116339","display_name":"Affimed Therapeutics (Germany)","ror":"https://ror.org/02fdw0g32","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210116339"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Kristina Ellwanger","raw_affiliation_strings":["Affimed Therapeutics AG, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affimed Therapeutics AG, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210116339"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112487504","display_name":"Melvyn Little","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Melvyn Little","raw_affiliation_strings":["retired, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"retired, Germany","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"15_suppl","first_page":"3068","last_page":"3068"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.7627000212669373,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.7627000212669373,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.14710000157356262,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.013500000350177288,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd19","display_name":"CD19","score":0.6079999804496765},{"id":"https://openalex.org/keywords/cd3","display_name":"CD3","score":0.8849999904632568},{"id":"https://openalex.org/keywords/t-cell-mediated-cytotoxicity","display_name":"T cell cytotoxicity","score":0.7639999985694885},{"id":"https://openalex.org/keywords/b-cell-malignancies","display_name":"B-cell malignancies","score":0.8820000290870667},{"id":"https://openalex.org/keywords/tetravalent-antibody","display_name":"tetravalent antibody","score":0.7419999837875366},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.6620000004768372},{"id":"https://openalex.org/keywords/cytokine-production","display_name":"cytokine production","score":0.7919999957084656},{"id":"https://openalex.org/keywords/tumor-cell-lysis","display_name":"tumor cell lysis","score":0.5659999847412109},{"id":"https://openalex.org/keywords/raji-cells","display_name":"Raji cells","score":0.5709999799728394},{"id":"https://openalex.org/keywords/nod-scid-xenograft","display_name":"NOD/SCID xenograft","score":0.7680000066757202},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.712201714515686},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.5638264417648315},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.5471290349960327},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5314955115318298},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.5118460059165955},{"id":"https://openalex.org/C79484868","wikidata":"https://www.wikidata.org/wiki/Q5971673","display_name":"IL-2 receptor","level":4,"score":0.49282410740852356},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4852449893951416},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.43778735399246216},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.43299245834350586},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.43045946955680847},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3842083811759949},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.38372722268104553},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.37601298093795776},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.31889432668685913},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.2837947607040405},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.21038520336151123},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08662548661231995}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.15_suppl.3068","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.3068","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.3068","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2336995415","https://openalex.org/W1943878720","https://openalex.org/W2026023404","https://openalex.org/W2548639060","https://openalex.org/W2966112968","https://openalex.org/W2319765449","https://openalex.org/W2622381531","https://openalex.org/W2559800744","https://openalex.org/W4232615027","https://openalex.org/W2898674861"],"abstract_inverted_index":{"3068":[0],"Background:":[1],"CD19,":[2],"due":[3],"to":[4,15,58,136,161,187,269,281],"broader":[5],"expression":[6],"on":[7,98],"B":[8,23],"cell":[9,24,100,131,175,192,219,245,291],"subtypes,":[10],"is":[11,172,267,325],"an":[12,339],"attractive":[13],"alternative":[14],"CD20":[16],"as":[17,319],"a":[18,77,111,137,304,311,326],"target":[19,130],"for":[20,47,86,332],"treatment":[21,334],"of":[22,129,166,174,195,206,223,231,308,314,335],"malignancies.":[25],"T":[26,56,142,157,191,200,218,244,290],"cells":[27,57,143,158,201,233],"are":[28,274],"potent":[29],"tumor-killing":[30],"effectors":[31],"that":[32],"cannot":[33],"be":[34],"recruited":[35],"by":[36,133,265],"full":[37,258],"length":[38,259],"antibodies,":[39],"however":[40],"TandAb":[41,53],"technology":[42],"harnesses":[43],"their":[44],"cytotoxic":[45],"nature":[46],"oncology":[48],"indications.":[49],"The":[50],"CD3":[51,88],"RECRUIT":[52],"AFM11":[54,134,178,198,212,248,266,286,302,315,324],"enables":[55],"potently":[59],"and":[60,65,89,94,102,127,155,189,215,221,228,239,293,343],"specifically":[61],"kill":[62],"CD19+":[63,99,207,232,242,270,336],"tumors":[64],"possesses":[66],"advantageous":[67,340],"PK":[68],"properties":[69],"enabling":[70],"intravenous":[71],"dosing.":[72],"Methods:":[73],"We":[74],"constructed":[75],"AFM11,":[76],"human":[78,118],"bispecific":[79,138],"tetravalent":[80],"antibody":[81],"with":[82,117,164,285,338],"two":[83],"binding":[84],"sites":[85],"both":[87,153],"CD19.":[90],"In":[91,105,121,209,300],"vitro":[92,122],"efficacy":[93,107,128,318],"safety":[95,341],"were":[96],"evaluated":[97,109],"lines":[101],"primary":[103],"tumors.":[104],"vivo":[106,301],"was":[108],"in":[110,203,277],"murine":[112],"NOD/scid":[113],"xenograft":[114],"model":[115],"reconstituted":[116],"PBMC.":[119],"Results:":[120],"assays":[123],"demonstrate":[124],"higher":[125],"potency":[126],"lysis":[132,163,264],"relative":[135],"tandem":[139],"scFv.":[140],"CD8+":[141,156],"dominate":[144],"early":[145],"cytotoxicity":[146,171,181,292],"(4":[147],"hrs)":[148],"while":[149],"after":[150],"24":[151],"hrs":[152],"CD4+":[154],"equally":[159],"contribute":[160],"tumor":[162],"EC50":[165],"0.5":[167],"\u2013":[168],"5":[169,320],"pM;":[170],"independent":[173],"CD19":[176],"density.":[177],"exhibits":[179,303,316],"similar":[180,317],"at":[182],"Effector:Target":[183],"ratios":[184],"from":[185,234],"5:1":[186],"1:5":[188],"facilitates":[190],"serial":[193],"killing":[194],"its":[196],"targets.":[197],"activates":[199],"only":[202],"the":[204,252,333],"presence":[205],"cells.":[208],"PBMC":[210,235],"cultures":[211],"induces":[213],"CD69":[214],"CD25":[216],"expression,":[217],"proliferation,":[220],"production":[222],"IFN-\u03b3,":[224],"TNF-\u03b1,":[225],"IL-2,":[226],"IL-6,":[227],"IL-10.":[229],"Depletion":[230],"abrogates":[236],"these":[237],"effects,":[238],"indicates":[240],"strict":[241],"target-dependent":[243],"activation.":[246],"Thus,":[247],"should":[249],"not":[250,275,288,297],"elicit":[251],"devastating":[253],"cytokine":[254],"release":[255],"observed":[256],"when":[257],"antibodies":[260],"bind":[261],"CD3.":[262],"Cell":[263],"restricted":[268],"targets":[271],"asCD19-":[272],"bystanders":[273],"lysed":[276],"co-culture":[278],"assays.":[279],"Up":[280],"one":[282],"week":[283],"co-incubation":[284],"does":[287,296],"inhibit":[289],"thus":[294],"it":[295],"induce":[298],"anergy.":[299],"dose-dependent":[305],"growth":[306],"inhibition":[307],"Raji":[309],"tumors;":[310],"single":[312],"dose":[313],"daily":[321],"injections.":[322],"Conclusions:":[323],"highly":[327],"efficacious":[328],"novel":[329],"drug":[330],"candidate":[331],"malignancies":[337],"profile":[342],"anticipated":[344],"dosing":[345],"regimen.":[346]},"counts_by_year":[{"year":2015,"cited_by_count":2}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2019-08-13T00:00:00"}